HBV Vaccines
HBV Vaccines
U.S. Hepatitis B Prevalence in the U.S. in the HBV Vaccine Era
- Details
- Category: HBV Prevention
- Published on Friday, 02 July 2010 12:49
- Written by Liz Highleyman
The prevalence of past and present hepatitis B virus (HBV) infection fell by nearly 70% among children in a large household survey of U.S. residents a decade after the introduction of universal HBV vaccination, according to a report by Centers for Disease Control and Prevention (CDC) researchers published in the July 15, 2010 Journal of Infectious Diseases. Hepatitis B prevalence among adults remains high, however, varying considerably among racial/ethnic groups and much greater among foreign-born individuals.
Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 04 June 2010 12:49
- Written by Dynavax
Dynavax Technologies announced this week that a Data Safety Monitoring Board has reviewed interim data from more than 2000 participants in 2 Phase 3 studies of the company's investigational hepatitis B vaccine, Hepislav, and determined that the trial may go forward without modification.
Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 12 May 2009 13:47
- Written by HIVandHepatitis.com
An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.
Web Design and Development by